within Pharmacolibrary.Drugs.ATC.R;

model R03BA06
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0006166666666666666,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0052,
    k12             = 25,
    k21             = 25
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03BA06</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Triamcinolone is a synthetic corticosteroid used primarily as an anti-inflammatory and immunosuppressant for the treatment of conditions such as asthma, allergic rhinitis, and other respiratory diseases. Under the ATC code R03BA06, it is utilized for inhalation therapy in respiratory disorders. Triamcinolone is approved for use in many countries, though its use may vary depending on availability and guideline recommendations.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult patients from non-inhaled triamcinolone models extrapolated to inhaled route due to lack of published specific PK data for inhaled triamcinolone acetonide (R03BA06).</p><h4>References</h4><ol><li><p>Derendorf, H, et al., &amp; Erdmann, M (1995). Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. <i>Journal of clinical pharmacology</i> 35(3) 302–305. DOI:<a href=&quot;https://doi.org/10.1002/j.1552-4604.1995.tb04064.x&quot;>10.1002/j.1552-4604.1995.tb04064.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7608322/&quot;>https://pubmed.ncbi.nlm.nih.gov/7608322</a></p></li><li><p>Argenti, D, et al., &amp; Heald, D (2000). A study comparing the clinical pharmacokinetics, pharmacodynamics, and tolerability of triamcinolone acetonide HFA-134a metered-dose inhaler and budesonide dry-powder inhaler following inhalation administration. <i>Journal of clinical pharmacology</i> 40(5) 516–526. DOI:<a href=&quot;https://doi.org/10.1177/00912700022009134&quot;>10.1177/00912700022009134</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10806605/&quot;>https://pubmed.ncbi.nlm.nih.gov/10806605</a></p></li><li><p>Derendorf, H, et al., &amp; Barth, J (1998). Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. <i>The Journal of allergy and clinical immunology</i> 101(4 Pt 2) S440–S446. DOI:<a href=&quot;https://doi.org/10.1016/s0091-6749(98)70156-3&quot;>10.1016/s0091-6749(98)70156-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9563369/&quot;>https://pubmed.ncbi.nlm.nih.gov/9563369</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03BA06;
